Hematologic dyscrasia associated with ticlopidine therapy: Evidence for causality

CMAJ. Canadian Medical Association Journal

Volumn 163, Issue 11, 2000, Pages 1441-1448

  Paradiso Hardy, F L ^a   Angelo, C M ^a   Lanctot, K L ^a   Cohen, E A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; DIGOXIN; DIPYRIDAMOLE; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; TICLOPIDINE;

AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; BLOOD DYSCRASIA; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PANCYTOPENIA; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA;

EID: 0034727687     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
2. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
3. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial
4. Prevention of aorta-coronary bypass graft occlusion C beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: A double-blind study
5. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs
6. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs [abstract]
7. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting
8. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary stents
9. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients
10. Ticlopidine: Blood and liver involvement?
11. Hematological toxicity of ticlopidine?
12. Cholestatic icterus and agranulocytosis due to ticlopidine
13. Deux observations d'agranulocytose aigue au cours d'un traitement anti-agregant par la ticlopidine
14. Anaemia and agranulocytosis associated with ticlopidine therapy
15. Agranulocytosis during a treatment with nitrendipine and ticlopidine
16. Agranulocytosis caused by ticlopidine and its mechanism
17. Hematological toxicity of ticlopidine
18. Comment: Pseudomonas bacteremia secondary to ticlopidine-induced agranulocytosis
19. Agranulocytosis associated with ticlopidine: A possible benefit with filgrastim
20. Ticlopidine induced agranulocytosis managed with granulocyte colony stimulating factor
21. Ticlopidine and severe aplastic anaemia
22. Ticlopidine and severe aplastic anaemia
23. Ticlopidine and severe aplastic anaemia
24. Ticlopidine and aplastic anaemia
25. Aplastic anaemia and ticlopidine
26. Ticlopidine and fatal aplastic anemia in an elderly woman
27. Ticlopidine and severe aplastic anemia
28. Fatal aplastic anemia associated with ticlopidine therapy C approaches to an adverse drug reaction
29. Prevention of ischemic stroke
30. Severe aplastic anemia induced by ticlopidine: Report of a case
31. Sustained granulocyte recovery after G-CSF in a patient with ticlopidine-induced severe aplastic anemia
32. Severe aplastic anemia due to ticlopidine
33. Aplastic anemia with ticlopidine therapy in two Chinese patients
34. Aplastic anemia associated with ticlopidine
35. Ticlopidine-induced aplastic anemia: Report of three Chinese patients and review of the literature
36. Probable ticlopidine-induced severe aplastic anemia and cholestatic hepatitis
37. Severe aplastic anemia induced by ticlopidine: Report of two cases
38. Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting
39. Aplastic anaemia induced by ticlopidine after placement of coronary artery stents
40. Leukopenia due to ticlopidine in a patient
41. Granulocyte colony-stimulating factor for neutropenia secondary to ticlopidine
42. Delayed neutropenia with ticlopidine
43. Fatal neutropenia and thrombocytopenia associated with ticlopidine
44. Pseudomonas bacteremia precipitated by ticlopidine-induced neutropenia
45. Neutropenia with ticlopidine plus aspirin
46. Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement
47. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting
48. Reversible bone-marrow suppression primarily involving granulopoiesis following the use of ticlopidine
49. Bone marrow aplasia associated with ticlopidine therapy
50. Ticlopidine-associated pancytopenia: Implications of an acetylsalicylic acid alternative
51. Bone marrow suppression and Klebsiella pneumonia septicemia due to ticlopidine and successful treatment with filgrastim; a case report
52. Thrombocytopenia due to antibodies induced by ticlopidine
53. Ticlopidine and thrombocytopenia
54. Thrombocytopenia and hepatitis complicating ticlopidine therapy
55. Thrombotic thrombocytopenic purpura related to ticlopidine
56. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine treatment: Case report
57. Thrombotic thrombocytopenic purpura developed during ticlopidine therapy
58. Thrombotic thrombocytopenic purpura associated with ticlopidine
59. Thrombotic thrombocytopenic purpura associated with ticlopidine
60. Ticlopidine and thrombotic thrombocytopenic purpura
61. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis
62. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
63. Ticlopidine-induced thrombotic thrombocytopenic purpura
64. Thrombotic thrombocytopenic purpura: A rare but potential life-threatening complication following ticlopidine administration
65. Thrombotic thrombocytopenic purpura associated with ticlopidine use: A report of 3 cases and review of the literature
66. Adverse drug reactions: A matter of opinion
67. The ambiguity of adverse drug reactions
68. Assessing causality of adverse drug reactions: Global introspection and its limitations
69. Postmarketing surveillance and adverse drug reactions. Current perspectives and future needs
70. A Bayesian assessment of idiosyncratic adverse reactions to new drugs: Guillain-Barre syndrome and zimeldine
71. The diagnosis of adverse medical events associated with drug treatment
72. The causality assessment of adverse drug reactions using a Bayesian approach
73. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: Report of an international consensus meeting
74. Risks of agranulocytosis and aplastic anemia: A first report of their relation to drug use with special reference to analgesics
75. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs: The International Agranulocytosis and Aplastic Anemia Study
76. Ticlopidine-induced neutropenia: Recognition and management
77. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors
78. Safety profiles of the anglotensin converting enzyme inhibitors captopril and enalapril
79. Incidence and clinical course of thromboric thrombocytopenic purpura due to ticlopidine following coronary stenting
80. Increasing mortality from thrombotic thrombocytopenic purpura in the United States C analysis of national mortality data, 1968-1991
81. The Bayesian differential diagnosis of neutropenia associated with antiarrhythmic agents
82. Time to act on drug safety
83. Frontiers in interventional cardiology
84. Possible mechanisms of action of ticlopidine on committed granulocyteBmacrophage precursor
85. Using microcomputers to simplify the Bayesian causality assessment of adverse drug reactions
86. Clopidogrel versus ticlopidine after intracoronary stent placement
87. Is clopidogrel a safe and effective adjunctive anti-platelet therapy for coronary artery stenting
88. The effectiveness of the combination of Plavix and Aspirin versus Ticlid and Aspirin after coronary stent implantation
89. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
90. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting
91. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
92. Thrombotic thrombocytopenic purpura associated with clopidogrel